Table 4 Variation of the measures used before and after COVID-19 period in patients with schizophrenia
From: Cognitive function in recovered COVID-19 Lebanese patients with schizophrenia
|  | Patients having COVID-19 (n = 71) | Patients without COVID-19 (n = 24) | ||||
|---|---|---|---|---|---|---|
Before COVID-19 period | After COVID-19 period | P -value | Before COVID-19 period | After COVID-19 period | p-value | |
Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |||
Clinical symptoms | ||||||
 Positive PANSS | 21.73 ± 10.25 | 17.38 ± 6.31 | 0.001 | 18.62 ± 8.54 | 17.37 ± 6.76 | 0.467 |
 Negative PANSS | 17.29 ± 8.04 | 13.63 ± 7.09 | 0.004 | 18.25 ± 7.98 | 13.70 ± 6.59 | 0.022 |
 General psychopathology PANSS | 47.63 ± 16.38 | 34.91 ± 11.10 |  < 0.001 | 45.00 ± 18.78 | 33.04 ± 11.33 | 0.002 |
Calgary scale (depression) | 4.88 ± 4.86 | 4.70 ± 4.76 | 0.748 | 5.04 ± 4.44 | 4.58 ± 4.51 | 0.665 |
ADL | 5.66 ± 0.79 | 5.63 ± 0.86 | 0.817 | 5.85 ± 0.54 | 5.83 ± 0.43 | 0.714 |
Chlorpromazine equivalent dose | 1069.21 ± 1178.24 | 1070.38 ± 1034.34 | 0.990 | 1622.00 ± 1208.56 | 1830.95 ± 1114.72 | 0.051 |
ADS score | 7.26 ± 3.08 | 7.19 ± 2.99 | 0.753 | 8.37 ± 3.49 | 8.00 ± 3.63 | 0.205 |